RxDoctor Payments Data

Jesus Pino Moreno, MD

Advanced Heart Failure and Transplant Cardiology · Honolulu, HINPI 1609280544

Payments from drug & device makers

$126,717in general payments, 2019–2025

Across 276 payments — averaging $459.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endotronix, Inc.$84K
  • E.r. Squibb & Sons, L.L.C.$28K
  • Abiomed$5K
  • Abbott$3K
  • Pfizer$1K
  • Boehringer Ingelheim$1K
  • plus $5K from 22 others

What the payments were for

  • Travel & lodging$1,2998%
  • Food & beverage$15,49691%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$72,743
Medicare patients
277
Services billed
615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis188$4,585,435
CamzyosMavacamten76$627,431
EntrestoSacubitril/Valsartan183$293,948
JardianceEmpagliflozin179$262,751
EliquisApixaban85$127,606
VerquvoVericiguat36$48,511
XareltoRivaroxaban25$29,819
FarxigaDapagliflozin Propanediol23$26,210
OzempicSemaglutide11$10,293
Everolimus13$9,602
Sirolimus18$6,955
Praluent PenAlirocumab11$5,485
Metoprolol Succinate310$5,251
Tacrolimus18$3,347
Mycophenolate Mofetil16$3,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$1,165$4,713,042273 claims
E.r. Squibb & Sons, L.L.C.Camzyos$27,524$627,43176 claims
NovartisEntresto$30$293,948183 claims
Boehringer IngelheimJardiance$1,149$262,751179 claims
MerckVerquvo$669$48,51136 claims
AstraZenecaFarxiga$400$26,21023 claims
Novo NordiskOzempic$294$10,29311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Honolulu

Where these figures come from

Is this you, or does something look wrong? →